Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cellectis

Sanofi reception

Sanofi gains access to antibody tech with Kymab acquisition

French pharma will receive global rights to phase 2a monoclonal antibody

- PMLiVE

bluebird bio to separate oncology and rare diseases units

New oncology company will be led by current bluebird bio CEO Nick Leschly

Delphi Technique Virtual Co-creation: A Customer Story

How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints.

Impetus Digital

- PMLiVE

Kite and Oxford BioTherapeutics sign oncology research pact

Agreement will focus on five novel drug targets across a range of indications

- PMLiVE

AZ/Oxford University COVID-19 vaccine wins emergency approval in India

In June 2020, AZ signed a licensing deal with the Serum Institute for the vaccine

- PMLiVE

First person in the UK given AstraZeneca/Oxford University COVID-19 vaccine

The vaccine can be stored at standard refrigerator temperatures

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Growing evidence supports the important role of biosimilars in healthcare

New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care

- PMLiVE

After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

Thanks to advances in technology and new commercial viability, cell and gene therapy is finally coming of age

- PMLiVE

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

British pharma company adds preclinical antibody to its pipeline

- PMLiVE

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Acquisition includes a number of candidates for neurodegenerative diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links